Consensus Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 19/10/2026 BST			5-day change	1st Jan Change
40.24 ^USD	+0.85%		-4.05%	-8.65%

10-08	Scholar Rock Resubmits Apitegromab Application in EU for Spinal Muscular Atrophy	MT
10-08	Scholar Rock Resubmits Apitegromab Marketing Authorisation Application To European Medicines Agency For Treatment Of Children And Adults With Spinal Muscular Atrophy	CI

Evolution of the Average Target: Scholar Rock Holding Corporation

Evolution of the Target Price: Scholar Rock Holding Corporation

Changes in Analyst Recommendations: Scholar Rock Holding Corporation

8c248088c543d575a81.koOPV3DPWvSlkmE2cF7hWVvM_-fztgFNFEaEimw3EdY._M6iYQP2F7zj-htsBjq-Fi_0yYqn8zV0TAzP2lpNX7nhsv0WQPgOzJD7Ag~4809bca3520f07f8eaac7a0ce0df3c9a

Analysts' recommendations: Scholar Rock Holding Corporation

09-25	Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says	MT
09-24	Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating	MT
09-15	Scholar Rock Shares Fall After Barclays Downgrade	MT
09-15	Barclays Downgrades Scholar Rock to Equalweight From Overweight, Adjusts PT to $58 From $55	MT
09-14	Wedbush Adjusts Price Target on Scholar Rock to $70 From $64, Keeps Outperform Rating	MT
09-14	Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating	MT
08-21	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
04-21	Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target	MT
03-31	Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating	MT
03-04	Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating	MT
03-03	Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating	MT
01-07	UBS Initiates Scholar Rock Holding at Buy With $60 Price Target	MT
11-14	Wedbush Adjusts Pt on Scholar Rock Holding to $50 From $43, Maintains Outperform Rating	MT
23/09/25	HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating	MT
23/09/25	Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says	MT
17/09/25	Barclays Initiates Scholar Rock at Overweight With $45 Price Target	MT
15/09/25	Leerink Partners Initiates Scholar Rock at Outperform With $51 Price Target	MT
06/08/25	Biopharma Scholar Rock Q2 net loss widens, no revenue	RE
18/07/25	Truist Raises Price Target on Scholar Rock Holding to $54 From $45, Keeps Buy Rating	MT
17/07/25	Cantor Fitzgerald Initiates Coverage on Scholar Rock With Overweight Rating	MT
27/02/25	Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating	MT
25/11/24	Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating	MT
25/11/24	Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating	MT
12/11/24	Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating	MT
08/10/24	Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SCHOLAR ROCK HOLDING CORPORATION					+75.04%
	WUXI APPTEC CO., LTD.					+30.97%
	LONZA GROUP AG					+13.23%
	ARGENX SE					+38.42%
	IQVIA HOLDINGS INC.					+13.19%
	BEONE MEDICINES AG					+17.91%
	REVOLUTION MEDICINES, INC.					+41.56%
	CELLTRION, INC.					+35.14%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+9.2%
	Average					+29.94%
	Weighted average by Cap.					+26.38%